A preliminary benefit-risk assessment of varenicline in smoking cessation.

Journal article

Varenicline is a recently developed medication for smoking cessation, which has been available on prescription since 2006. It is a selective nicotinic acetylcholine receptor partial agonist, and is designed to reduce withdrawal symptoms and to lessen the rewards of continued smoking. Our objective in this article is to assess the efficacy of varenicline as an aid to smoking cessation and to weigh the potential benefits against the possible risks. We identified ten randomized controlled trials...

Expand abstract

Authors: Cahill, K; Stead, L; Lancaster, T

• Publication status: Published
• Journal: Drug safety
• Volume: 32
• Issue: 2
• Pages: 119-135
• Publication date: 2009-01-01
• DOI: 10.2165/00002018-200932020-00005
• ISSN: 0114-5916
• Language: English
• Keywords: Recurrence; Risk Assessment; Benzazepines; Nicotine; Smoking; Nicotinic Agonists; Quinoxalines; Humans; Substance Withdrawal Syndrome; Bupropion; Antidepressive Agents, Second-Generation; Smoking Cessation; Product Surveillance, Postmarketing